VRDN - NASDAQ
Viridian Therapeutics, Inc.
$16.92
+6.6%Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
At a Glance
Live Snapshotvrdn
Stock Based Compensation
Last Annual Value
44.30M
3-Year CAGR
31%
5-Year CAGR
65%
10-Year CAGR
31%
Viridian Therapeutics, Inc. Competitors Analysis of Stock Based Compensation
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Viridian Therapeutics, Inc. NASDAQ:VRDN | 44.30M | -13.0% | 25.1% | 35.6% | |
 uniQure N.V. NASDAQ:QURE | 17.68M | -20.4% | -7.2% | 11.0% | |
 Cogent Biosciences, Inc. NASDAQ:COGT | 46.08M | 14.6% | 31.6% | 46.4% | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 37.93M | 48.9% | 66.0% | N/A | |
 Edgewise Therapeutics, Inc. NASDAQ:EWTX | 0.00 | N/A | N/A | N/A | |
 Structure Therapeutics Inc. NASDAQ:GPCR | 28.99M | 52.4% | 81.1% | N/A | |
 Arcus Biosciences, Inc. NYSE:RCUS | 60.00M | -6.3% | 1.8% | 91.6% | |
 Ocular Therapeutix, Inc. NASDAQ:OCUL | 43.18M | 34.3% | 23.6% | 21.9% | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 36.22M | 14.9% | 32.2% | 9.0% | |
 ImmunityBio, Inc. NASDAQ:IBRX | 0.00 | N/A | N/A | N/A |
Viridian Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your VRDN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.